AVGR
Avinger Inc.
Healthcare•Medical Devices
Watchlist:
Last updated: Saturday 15th February 2025
0.00
No Change
Prev Close:N/A
Open:0.5561
Bid:N/A
Ask:0.475
52 Week Range
0.000.00
Volume:0
Mkt Cap:0 M
Financials
Financial Statements
AVGR - Cash Flow (Annual)
| Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Invalid date | |
|---|---|---|---|---|---|---|---|---|---|---|
| (increase) Decrease In Inventories | -802000.0 | -1 M | -849000.0 | -490000.0 | -1 M | -92000.0 | -1 M | -6 M | -2 M | |
| (increase) Decrease In Other Current Assets | -43000.0 | 5000.0 | -16000.0 | 340000.0 | -475000.0 | 13000.0 | -35000.0 | |||
| (increase) Decrease In Other Current Liabilities | 575000.0 | -7000.0 | -34000.0 | -260000.0 | ||||||
| (increase) Decrease In Other Working Capital | 779000.0 | 441000.0 | 532000.0 | -2000.0 | ||||||
| (increase) Decrease In Payables | 146000.0 | -764000.0 | 679000.0 | 31000.0 | -485000.0 | -125000.0 | 1 M | 470000.0 | 84000.0 | |
| (increase) Decrease In Receivables | 75000.0 | 269000.0 | 89000.0 | -1000.0 | -248000.0 | -160000.0 | 2 M | -2 M | 7000.0 | |
| Asset Impairment Charge | 404000.0 | 272000.0 | 125000.0 | 528000.0 | 272000.0 | 914000.0 | 6 M | 800000.0 | -26000.0 | |
| Capital Expenditure Reported | 8000.0 | 51000.0 | 34000.0 | 88000.0 | 32000.0 | 45000.0 | 971000.0 | 577000.0 | ||
| Cash At Beginning Of Period | 15 M | 19 M | 22 M | 11 M | 16 M | 5 M | 36 M | 43 M | 12 M | |
| Cash At End Of Period | 5 M | 19 M | 19 M | 22 M | 27 M | 16 M | 5 M | 36 M | 43 M | |
| Cash Flow | -14 M | -17 M | -16 M | -15 M | -17 M | -18 M | -34 M | -53 M | -41 M | |
| Cash Flow From Continuing Investing Activities | -8000.0 | -51000.0 | -34000.0 | 65000.0 | -70000.0 | -4000.0 | -41000.0 | -971000.0 | -322000.0 | |
| Change In Account Payable | 146000.0 | -764000.0 | 679000.0 | 31000.0 | -485000.0 | -125000.0 | -334000.0 | 470000.0 | 84000.0 | |
| Change In Accrued Expense | 160000.0 | -61000.0 | 49000.0 | 15000.0 | -795000.0 | -2 M | -1 M | -191000.0 | -962000.0 | |
| Change In Interest Payable | 49000.0 | 15000.0 | -795000.0 | -2 M | -1 M | -191000.0 | -962000.0 | |||
| Change In Payables And Accrued Expense | 306000.0 | -825000.0 | 728000.0 | 46000.0 | -1 M | -2 M | 221000.0 | 279000.0 | -878000.0 | |
| Change In Prepaid Assets | -213000.0 | -62000.0 | 50000.0 | -48000.0 | 128000.0 | 5000.0 | 22000.0 | -130000.0 | -363000.0 | |
| Change In Working Capital | 145000.0 | -2 M | 550000.0 | -495000.0 | -3 M | -2 M | 905000.0 | -7 M | -4 M | |
| Changes In Account Receivables | 75000.0 | 269000.0 | 89000.0 | -1000.0 | -248000.0 | -160000.0 | 2 M | -2 M | 7000.0 | |
| Depreciation | 289000.0 | 196000.0 | 687000.0 | 897000.0 | 890000.0 | 1 M | 1 M | 2 M | 1 M | |
| Depreciation Unreconciled | 372000.0 | 279000.0 | 773000.0 | 1 M | 1 M | 1 M | 2 M | 2 M | 1 M | |
| Depreciation And Amortization | 372000.0 | 196000.0 | 687000.0 | 897000.0 | 1 M | 1 M | 2 M | 2 M | 1 M | |
| Financing Cash Flow | 5 M | 12 M | 13 M | 26 M | 12 M | 29 M | 4 M | 47 M | 72 M | |
| Free Cash Flow | -14 M | -17 M | -16 M | -15 M | -17 M | -18 M | -35 M | -54 M | -41 M | |
| Gain Loss On Investment Securities | -835000.0 | |||||||||
| Gain Loss On Sale Of PPE | -7000.0 | 18000.0 | ||||||||
| Interest Paid Supplemental Data | 60000.0 | 4 M | 4 M | 6 M | ||||||
| Issuance Of Capital Stock | 4 M | 314000.0 | 246000.0 | 37 M | 64 M | |||||
| Issuance Of Capital Stock | 4 M | 314000.0 | 246000.0 | 37 M | 64 M | |||||
| Issuance Of Debt | 2 M | -25000.0 | 10 M | 1 M | ||||||
| Net Cash From Financing Activities | 5 M | 24 M | 13 M | 26 M | 28 M | 29 M | 4 M | 47 M | 72 M | |
| Net Cash From Investing Activities | -8000.0 | -51000.0 | -34000.0 | 65000.0 | -70000.0 | -4000.0 | -41000.0 | -971000.0 | -322000.0 | |
| Net Cash From Operating Activities | -14 M | -17 M | -16 M | -15 M | -17 M | -18 M | -34 M | -53 M | -41 M | |
| Net Change In Cash & Cash Equivalents | -9 M | -5 M | -3 M | 11 M | -5 M | 11 M | -31 M | -7 M | 31 M | |
| Net Income From Continuing Operations | -18 M | -18 M | -17 M | -19 M | -19 M | -28 M | -49 M | -56 M | -47 M | |
| Net Common Stock Issuance | 4 M | 314000.0 | 246000.0 | 37 M | 64 M | |||||
| Net Investment Properties Purchase And Sale | 255000.0 | |||||||||
| Net Investment Purchase And Sale | 255000.0 | |||||||||
| Net Issuance Payments Of Debt | 2 M | -25000.0 | 10 M | 1 M | ||||||
| Net Long Term Debt Issuance | 2 M | -25000.0 | 10 M | 1 M | ||||||
| Net PPE Purchase And Sale | -8000.0 | -51000.0 | -34000.0 | 65000.0 | -70000.0 | -4000.0 | -41000.0 | -971000.0 | -577000.0 | |
| Net Preferred Stock Issuance | 5 M | 24 M | 13 M | 24 M | 4 M | 26 M | 6 M | |||
| Operating (gains) Losses | 42000.0 | -208000.0 | -2 M | -79000.0 | 585000.0 | 334000.0 | -2 M | -275000.0 | 1 M | |
| Other Financing Charges Net | 36000.0 | 16 M | 3 M | 4 M | ||||||
| Other Investing Changes Net | 255000.0 | |||||||||
| Other Non-cash Items | 3 M | 2 M | 3 M | 4 M | 3 M | 10 M | 14 M | 9 M | 7 M | |
| Pension And Employee Benefit Expense | 42000.0 | -208000.0 | -94000.0 | -79000.0 | 585000.0 | 334000.0 | -2 M | -275000.0 | 2 M | |
| Preferred Stock Issuance | 5 M | 24 M | 13 M | 24 M | 4 M | 26 M | 6 M | |||
| Proceeds From Issuance Of Warrants | 8 M | 581000.0 | 323000.0 | |||||||
| Purchase Of Property Plant & Equipment | -8000.0 | -51000.0 | -34000.0 | 65000.0 | -70000.0 | -4000.0 | -41000.0 | -971000.0 | -577000.0 | |
| Purchase Of Short Term Investments | 2 M | 10 M | 29 M | |||||||
| Purchase Of PPE | -8000.0 | -51000.0 | -34000.0 | -88000.0 | -32000.0 | -45000.0 | -971000.0 | -577000.0 | ||
| Repayment Of Debt | -25000.0 | -27000.0 | -28 M | |||||||
| Repayment Of Debt | -25000.0 | -27000.0 | -28 M | |||||||
| Revenue Per Share | 83000.0 | 83000.0 | 86000.0 | 168000.0 | 171000.0 | 117000.0 | 218000.0 | 222000.0 | 199000.0 | |
| Sale Of PPE | 65000.0 | 18000.0 | 28000.0 | 4000.0 | ||||||
| Stock Based Compensation | 940000.0 | 127000.0 | 1 M | 2 M | 2 M | 3 M | 5 M | 7 M | 6 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.